tradingkey.logo

Tempest Therapeutics Inc <TPST.OQ> expected to post a loss of $3.51 a share - Earnings Preview

ReutersMay 14, 2025 11:04 AM
  • Tempest Therapeutics Inc TPST.OQ TPST.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025

  • ​LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of $3.51 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 1.3% in the last three months. ​

  • Wall Street's median 12-month price target for Tempest Therapeutics Inc is $65.00​, above​ its last closing price of $6.79. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-2.47

-3.29

-3.16

Beat

4

Dec. 31 2025

-3.25

-3.28

-4.03

Missed

-23

Sep. 30 2024

-4.56

-4.71

-5.33

Missed

-13.3​

Jun. 30 2024

-5.78

-5.24

-5.46

Missed

-4.2

​​Mar. 31 2024

-4.98

-4.86

-4.68

Beat

3.8

Dec. 31 2023

-4.81

-5.02

-4.94

Beat

1.5​

Sep. 30 2023

-7.25

-7.45

-6.24

Beat

16.2

Jun. 30 2023

-7.15

-6.73

-7.02

Missed

-4.3

This summary was machine generated May 14 at 11:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles